See hidden discussions | Win great prizes | Get free support
I think it speaks to after being exposed to the vaccine it may cause ones immune system down the line to enhance the effectiveness of the virus if one is exposed to the virus a while after the vaccine.
It's quite simple to know if you're likely going to have an "adverse reaction" or not: From the U.S. Government's VAERS (Vaccine Adverse Event Reporting System) database it can be noted that all the toxic batches (Base toxicity is defined as – the toxicity of batches generating 1 adverse reaction report = the toxicity of 70% of all reported batches) have similar labels.
Here is the evidence summarized (further links to be found under the video in the description section at the link) ...
COVID Vaccine Batch Numbers Code for Toxicity
Poor kids, from the article:Thanh Hoa has suspended the use of a Pfizer Covid-19 vaccine batch after over 120 students were hospitalized following their inoculation.e.vnexpress.net
"This Japanese data shows that the spike protein of the Pfizer ‘vaccine’ gets into the blood where it circulates for several days post-vaccination and then accumulated in organs and tissues including the spleen, bone marrow, the liver, adrenal glands, and in the ovaries."
"Once in circulation, the spike protein can attach to specific ACE2 receptors that are on blood platelets and the cells that line blood vessels. This can either cause platelets to clump, and that can lead to clotting. It can also lead to bleeding."
"Research suggests this could lead to the production of spike protein in unintended places, including the brain, ovaries and spleen, which may cause the immune system to attack organs and tissues resulting in damage, and raises serious questions about genotoxicity and reproductive toxicity risks associated with the vaccine."
Please see below our responses to your question.
The downloaded report from the link you provided appears to be from the common technical document (CTD) presumably submitted to Japan’s Pharmaceuticals and Medical Devices Agency. The document is in Japanese and has not been evaluated but based on the tables/figures in the document it appears to be an amalgamation of different reports the MHRA and the European Medicines Agency (EMA) have previously reviewed. These studies are summarised in the MHRA and EMA public assessment reports which provide the basis for approval of the vaccine. Links to these are provided below: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19 https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
The study you highlight in your question is a tissue distribution study using a [3H]-labelled lipid nanoparticle-mRNA formulation containing the lipids ALC-0315 and ALC-0159 following intramuscular administration in rats. In this study the greatest concentration of radioactivity was found remaining in the injection site at each time point, with low levels of radioactivity detected in most tissues. It should be noted that the distribution of the lipid nanoparticles was measured using a radioactive label (tritium) in a lipid component. The data do not allow a judgment on the distribution of the mRNA component or expression and distribution of the encoded COVID-19 spike protein.
Whilst the lipid was widely distributed, the amounts outside the injection site and liver were small and were not associated with any adverse effects. In the repeated dose preclinical toxicity studies, no adverse effects outside of the expected inflammation associated with an immune response were detected.